fda update tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA Faces Law Suit Over

Gastrointestinal Symptoms: Common side effects include nausea, vomiting, diarrhea, and abdominal discomfort

Resistance training two to three times per week, even at moderate intensity, dramatically reduces lean mass loss during weight loss

The exceptions: PT-141 for women uses 1.75 mg subcutaneously (the FDA-approved Vyleesi dose), which differs from the research doses listed for men

Read: Direct Meds Delivers Affordable Access to Prescription Weight Loss Medications What Are GLP-1 Medications and How Do They Work

What is less established: the very long-term (beyond five years) safety of dual GIP and GLP-1 action, and whether the bone density changes seen with significant weight loss on any medication apply to tirzepatide with the same magnitude